Edition:
United Kingdom

Jiangsu Hengrui Medicine Co Ltd (600276.SS)

600276.SS on Shanghai Stock Exchange

79.81CNY
18 Sep 2019
Change (% chg)

¥0.78 (+0.99%)
Prev Close
¥79.03
Open
¥79.00
Day's High
¥80.10
Day's Low
¥78.68
Volume
15,819,986
Avg. Vol
17,924,316
52-wk High
¥81.25
52-wk Low
¥41.48

Latest Key Developments (Source: Significant Developments)

Jiangsu Hengrui Medicine Says H1 Net Profit Up 26.3% Y/Y
Thursday, 29 Aug 2019 

Aug 29 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>::SAYS H1 NET PROFIT UP 26.3% Y/Y.  Full Article

Jiangsu Hengrui Medicine Says Its 2018 Net Profit Up 26.4 Percent Y/Y
Friday, 15 Feb 2019 

Feb 15 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>::SAYS ITS 2018 NET PROFIT UP 26.4 PERCENT Y/Y AT 4.065 BILLION YUAN ($600.38 million).  Full Article

Jiangsu Hengrui Medicine to pay A shares div for FY 2017 on May 30
Thursday, 24 May 2018 

May 24 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS> ::* Says it will pay cash dividend of 0.13 yuan(before tax)/share and distribute 0.2 stock dividend/share as well as use additional paid-in capital to distribute 0.1 new shares for every share for 2017 to shareholders of record on May 29.* The company's shares will be traded ex-right and ex-dividend on May 30 and the dividend will be paid on May 30.  Full Article

Jiangsu Hengrui Says Q1 Net Profit Up 16.95 Percent Y/Y
Thursday, 26 Apr 2018 

April 26 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>::SAYS Q1 NET PROFIT UP 16.95 PERCENT Y/Y.  Full Article

Jiangsu Hengrui Medicine unit passes U.S. FDA approval
Friday, 2 Mar 2018 

March 2(Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says co's unit Shanghai Hengrui Pharmaceutical Co Ltd received FDA approval for desflurane for inhalation (product) from U.S. Food and Drug Administration.Says unit will be able to sell the product in U.S. after receiving the FDA approval.  Full Article

Jiangsu Hengrui Medicine receives GMP certificate
Wednesday, 28 Feb 2018 

Feb 28 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS> ::* Says it received goods manufacture practice (GMP) certificate from Health and Youth Care Inspectorate.* Certificate issued iodixanol injection, oxaliplatin for injection and caspofungin acetate for injection as well as Letrozole Tablets manufactured by the company and the valid period is until Sep. 2020.  Full Article

TG Therapeutics, Jiangsu Hengrui Announce Agreement For BTK Inhibitor Program For Treatment Of Hematologic Malignancies
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>::TG THERAPEUTICS AND JIANGSU HENGRUI MEDICINE ANNOUNCE GLOBAL LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NOVEL BTK INHIBITOR PROGRAM FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES.TG THERAPEUTICS INC - ‍ UNDER TERMS, HENGRUI WILL RECEIVE AN UP-FRONT LICENSING FEE AND NEAR-TERM MILESTONES, PAYABLE IN TG COMMON STOCK​.TG THERAPEUTICS INC - ‍HENGRUI IS ELIGIBLE TO RECEIVE COLLABORATION AND LICENSING PAYMENTS OF ABOUT $350 MILLION, IN ADDITION TO ROYALTIES ON FUTURE SALES​.  Full Article

Jiangsu Hengrui Medicine says license agreement on JAK1 inhibitor SHR0302 with U.S.-based firm Arcutis
Friday, 5 Jan 2018 

Jan 5(Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says co signs license agreement with U.S.-based firm Arcutis regarding JAK1 inhibitor SHR0302 .Says co grants Arcutis an exclusive right to develop and sell JAK1 inhibitor SHR0302 in United States of America, European Union and Japan.Says co will receive upfront and milestones payment of up to $223 million and sales commissions from Arcutis.  Full Article

Jiangsu Hengrui Medicine passes U.S. FDA approval
Wednesday, 29 Nov 2017 

Nov 29(Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says it received FDA approval for Dexmedetomidine Hydrochloride Injection from U.S. Food and Drug Administration.Company will be able to sell its Dexmedetomidine Hydrochloride Injection in the United States after receiving the FDA approval.  Full Article

Jiangsu Hengrui Medicine gets approval for clinical trials of drugs
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says it gets clinical trials approval for its drug named Seebri® Breezhaler® from China Food and Drug Administration.  Full Article

China, Hong Kong stocks firm on trade hopes

SHANGHAI, Aug 23 China and Hong Kong stocks rose on Friday, bolstered by hopes for potential progress in Sino-U.S. trade negotiations as the United States still plans in-person talks next month.